Impact of sertraline daily treatment regimen on adherence, persistence and healthcare resource utilisation in patients with major depressive disorder or obsessive-compulsive disorder: A real-world evidence analysis from the United States.

International Journal of Clinical Practice
Gang WangWei Yu

Abstract

To generate real-world evidence (RWE) from the United States to assess the impact of pill burden and the importance of achieving a stable daily dose of sertraline (time taken, number of dose adjustments needed) on adherence/persistence and healthcare resource utilisation (HCRU). Retrospective analysis of the PharMetrics® Plus database (1 October 2012 to 31 March 2020) in the United States. Eligible patients had major depressive disorder (MDD) or obsessive-compulsive disorder (OCD) and ≥1 claim for sertraline during index period (1 April 2013 to 31 March 2019, allowing 6-months prior, 1-year post-index follow-up). Patients who achieved stable daily dose of sertraline (>90 days on same dose) were categorised into five cohorts, depending on pill burden/daily dose: Cohort (1): 1 × 50 mg/d; Cohort (2): 1 × 100 mg/d; Cohort (3): 2 × 50 mg/d; Cohort (4): 1.5 × 100 mg/d; Cohort (5): 3 × 50 mg/d. Impact of pill burden on adherence/persistence and HCRU was assessed among cohorts using logistic regression analysis, and between patients who did vs did not stabilise on therapy. P < .05 was considered significant for all analyses. Of 224 412 eligible patients, 108 729 stabilised on sertraline (50, 100 or 150 mg/d) and formed Cohorts 1-5. Sta...Continue Reading

References

Sep 15, 2000·The Psychiatric Clinics of North America·N AttiullahS A Rasmussen
Dec 1, 2001·Psychiatric Services : a Journal of the American Psychiatric Association·J A SireyB S Meyers
Apr 10, 2002·Acta Psychiatrica Scandinavica·Ravi Lingam, Jan Scott
Oct 11, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Koen Demyttenaere
May 3, 2006·The Psychiatric Clinics of North America·Daniel A Geller
Oct 25, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowJohann Vega
Nov 3, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·T SanglierM Toumi
Apr 2, 2013·Clinical Therapeutics·Anne M LibbyJan D Hirsch
Jan 1, 2013·International Journal of Bipolar Disorders·Rita BauerMichael Bauer
Feb 14, 2015·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael BauerUNKNOWN Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders
Jun 13, 2015·Neuropsychiatric Disease and Treatment·Sabrina Anne JacobMohamed Azmi Ahmad Hassali
Apr 4, 2017·International Journal of Psychiatry in Clinical Practice·Michael BauerUNKNOWN WFSBP Task Force on Unipolar Depressive Disorders
Mar 13, 2018·Research in Social & Administrative Pharmacy : RSAP·Pornchanok SrimongkonTimothy F Chen
Feb 23, 2019·The Lancet. Psychiatry·Yueqin HuangYue Wu
Aug 3, 2019·Nature Reviews. Disease Primers·Dan J SteinH Blair Simpson
Aug 28, 2019·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yuncheng ZhuYiru Fang
Nov 21, 2019·Journal of Affective Disorders·Binbin YuXin Liu
Jul 1, 2020·The Journal of Clinical Psychiatry·Emily J FawcettJonathan M Fawcett

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.